Please login to the form below

Nippon Shinyaku

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Nippon Shinyaku's Japan sales performance.

Biosimilar Remicade reaches market in Japan and India

India. In Japan, Nippon Kayaku has launched a biosimilar version of Remicade (infliximab) originally developed by South Korean biotechnology company Celltrion, which was approved for marketing in July. ... Nippon Kayaku said infliximab is the second

Deal Watch table for September 2013

50. 5. Shin Nippon Biomedical / Transcept Pharma. Licence. TO-2070 nasal powder for acute migraine.

First biosimilar mAb gets the nod in EU

In Japan the drug will be co-marketed by Celltrion's development partner Nippon Kayaku. .

New formulations of Pralia and Enbrel head list of new drugs in Japan

line extension - which like its predecessor will be co-promoted by Nippon Boehringer Ingelheim - is expected to provide better control of high blood pressure over 24 hours.

An eye towards the biobetter in South Korea

Location. Status. Herceptin (trastuzumab). CT-P6. Celltrion. Hospira, Nippon Kayaku. Breast cancer. ... Remsima. Celltrion. Hospira, Nippon Kayaku. RA, AS, CD, PA, PS, &UC.

1 2 3 [ Next 5 results ]

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology

Featured jobs

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Director, Medical Education: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Account Director – Health Policy – Global Agency: Salary TBC

Global Business Development Director – Health Education: excellent commission

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Account Director, Healthcare Marketing Agency: Salary TBC

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Business Director: Competitive Salary Offered

Client Services Director – Medical Education Agency – North West...: Salary TBC

Medical Writer: Salary TBC

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Associate Director: £75, 000-90, 000

Account Manager / Account Director: Competative

Account Manager / Senior Account Manager: 35, 000-40, 000

Senior Medical Writer: Salary TBC

Account Director – Healthcare Marketing – Berks: Salary TBC

Senior Account Manager: Competitive Salary Offered

Account Director: Competitive Salary Offered

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?: Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement: Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape: Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....